DOI: /ICJ (Dengue fever) [2] (Aedes aegypti) (Aedes albopictus) (Dengue. (Flavivirus) 50 nm. ssrna) (capsid, C) ( ) (membrane, prm/m)
|
|
- Philip Holmes
- 5 years ago
- Views:
Transcription
1 210 DOI: /ICJ T (Dengue fever) [1] [2] ,000 [3] [4] 2015 ( ) (Aedes aegypti) (Aedes albopictus) (Dengue virus) (Flaviviridae) (Flavivirus) 50 nm 11 kb RNA ((+) ssrna) (capsid, C) ( ) (membrane, prm/m)
2 211 (envelope, E) (NS1, NS2a, NS2b NS3, NS4a, NS4b, NS5) [5] I II III IV 2013 Nikos Vasilakis 2 9 (Dengue hemorrhagic fever, DHF) (Dengue shock syndrome, DSS) [6] (Antibodydependent enhancement, ADE) T (Antigenic sin) [7] T T
3 212 Trop Med Health [19] 1940 Sabin Schlesinger [8] 1970 DNA ( ) (live attenuated vaccine) (chimeric live attenuated vaccine) (inactivated purified vaccine) (recombinant protein vaccine) DNA (DNA vaccine) (subunit vaccine) [9]
4 213 Immune Epitope Database and Analysis Resource [10] DENV1-4 (TetraVax- DV) % TV003 [11] TV005 TV003 [12]
5 214 (sanofi) (CYD-TDV) 17D (YFV- 17D) ( prm/e) [4] Dengvaxia ~45 [13] DENVax (Takeda Pharmaceuticals) DENV-2 prm/e DENV-2 [14] (GlaxoSmith-Kline GSK) TDEN-PIV VERO AS03B AS01E [15] DNA (Envelope proteins, E) (U.S Navy Medical Research Center) DENV-1 DNA Vical DNA (Vaxfectin ) [16] (envelope protein domain III, ED3) ED3 [20] [21] ED3 (lipoprotein) ED3
6 215 [22] (nonstructural protein, NS1) [17] [23] T (ED3) ED3 DNA ED3 ED3 ED3 CD4 + T T T T (major histocompatibility complex, MHC) T CD4 + T CD4 + T DENV2 T T ED3 ED3 T ED3 CD4 + T E E ( ) T T INF-r E T T T IFN-r
7 216 T [18] (2016) [4] 1. Messina JP, Brady OJ, Scott TW, et al: Global spread of dengue virus types: mapping the 70 year history.trends Microbiol 2014;22: Brady OJ, Gething PW, Bhatt S, et al: Refining the global spatial limits of dengue virus transmission by evidence-based consensus. PLoS Negl Trop Dis 2012;6: Thomas SJ, Endy TP: Vaccines for the prevention of dengue: development update. Hum Vaccin 2011;7: 彣 2016: Guzman MG, Halstead SB, Artsob H, et al: Dengue: a continuing global threat. Nat Rev Microbiol 2010;8:S Kyle JL, Harris E: Global spread and persistence of dengue. Annu Rev Microbiol 2008;62; Wahala WM, Silva AM: The human antibody response to dengue virus infection. Viruses 2011;3: Sabin AB, Schlesinger RW: Production of immunity to dengue with virus modified by propagation in mice. Science 1945;101: ;31: Lindow JC, Durbin AP, Whitehead SS,et al: Vaccination of volunteers with low-dose, liveattenuated, dengue viruses leads to serotypespecific immunologic and virologic profiles. Vaccine 2013;31: Beaumier CM, Gillespie PM, Hotez PJ, et al: New vaccines for neglected parasitic diseases and dengue. Transl Res 2013;162: Whitehead SS: Development of TV003/TV005, a single dose, highly immunogenic live attenuated dengue vaccine; what makes this vaccine different from the Sanofi-Pasteur CYD vaccine? Expert Rev Vaccines 2016;15: Hadinegoro SR, Arredondo-García JL, Capeding MR,et al: Efficacy and long-term safety of a dengue vaccine in regions of endemic disease. N Engl J Med 2015;373: Osorio LE, Velez ID, Thomson C, et al: Safety and immunogenicity of a recombinant live attenuated tetravalent dengue vaccine (DENVax) in flavivirus-naive healthy adults in Colombia: a randomised, placebo-controlled, phase 1 study. Lancet Infect Dis 2014;14: Yauch LE, Shresta S: Dengue virus vaccine development. Adv Virus Res 2014;88: Li XF, Deng YQ, Yang HQ, et al: A chimeric dengue virus vaccine using Japanese encephalitis virus vaccine strain SA as backbone is immunogenic and protective against either parental virus in mice and nonhuman primates. J Virol 2013;87: Chen MC, Lin CF, Lei HY, et al: Deletion of the C-terminal region of dengue virus nonstructural protein 1 (NS1) abolishes anti-ns1-mediated platelet dysfunction and bleeding tendency. J Immunol 2009;183: C h e n H W, H u H M, Wu S H, e t a l : T h e
8 217 immunodominance change and protection of CD4+ T-cell responses elicited by an envelope protein domain III-based tetravalent dengue vaccine in mice. PLoS ONE 2015;10:e Moi ML, Takasaki T, Kurane I, et al: Human antibody response to dengue virus: implications for dengue vaccine design. Trop Med Health 2016;14:44: Leng CH, Liu SJ, Tsai JP, et al: A novel dengue vaccine candidate that induces cross-neutralizing antibodies and memory immunity. Microbes Infect 2009;11: Chen HW, Liu SJ, Li YS, et al: A consensus envelope protein domain III can induce neutralizing antibody responses against serotype 2 of dengue virus in non-human primates. Arch Virol 2013;158: Chen HW, Liu SJ, Liu HH, et al: A novel technology for the production of a heterologous lipoprotein immunogen in high yield has implications for the field of vaccine design. Vaccine 2009;27: ( ) d=cf7f90dcbcd5718d&nowtreeid=f94e6af8daa9fc 01&tid=CB9434C4FE5DB0BA 24. Roehrig JT, Risi PA, Brubaker JR, et al: T-helper cell epitopes on the E-glycoprotein of dengue 2 Jamaica virus. Virology 1994;198: L e c l e r c C, D é r i a u d E, M e g r e t F, e t a l : Identification of helper T cell epitopes of dengue virus E-protein. Mol Immunol 1993;30: Roehrig JT, Johnson AJ, Hunt AR, et al: Enhancement of the antibody response to flavivirus B-cell epitopes by using homologous or heterologous T-cell epitopes. J Virol 1992;66: Roehrig JT, Risi PA, Brubaker JR,et al: T-helper cell epitopes on the E-glycoprotein of dengue 2 Jamaica virus. Virology 1994;198: Nascimento EJ, Mailliard RB, Khan AM, et al: Identification of conserved and HLA promiscuous DENV3 T-cell epitopes. PLoS Negl Trop Dis 2013;7:e
Immune protection against dengue infection. Vaccine performance
Immune protection against dengue infection. Vaccine performance SCOTT B HALSTEAD MD Department of Preventive Medicine Uniformed Services University of the Health Sciences TOPICS Current dengue vaccines:
More informationDengue Vaccine. Irani Ratnam The Royal Melbourne Hospital & Peter Doherty Institute
Dengue Vaccine Irani Ratnam The Royal Melbourne Hospital & Peter Doherty Institute No Conflicts of interest Dengue Dengue virus (DENV), a member of the genus Flavivirus Vector-borne disease transmitted
More informationDengue and Zika vaccine development
Dengue and Zika vaccine development Carolyn E. Clark, PhD, MPH Scientist, Infection Control and Environmental Health Norwegian Institute of Public Health Kurs i import- og reisemedisin for helsepersonell
More informationDengue: The next vaccine preventable disease? Prof John McBride James Cook University
Dengue: The next vaccine preventable disease? Prof John McBride James Cook University Dengue viruses A flavivirus ~11kb genome, ~50nm diameter, lipid envelope. Gene order 5 C-prM-E-NS1 Four serotypes (1-4)
More informationdengue virus DENV DENV-1 DENV-2 DENV-3 DENV-4 NS1 Non-structural protein 1 NS1 DENV antibody-dependent enhancement ADE DENV
2018 9 59 17 Journal of Traditional Chinese Medicine 2018 Vol. 59 No. 17 1523 DOI 10. 13288 /j. 11-2166 /r. 2018. 17. 021 1 1 dengue virus DENV A B C 2009 WHO 1 2014 2 3 2018 DENV 1 antibody-dependent
More informationResults of Phase III Efficacy Studies in Dengue Endemic Regions of the Sanofi Pasteur Candidate Dengue Vaccine
Results of Phase III Efficacy Studies in Dengue Endemic Regions of the Sanofi Pasteur Candidate Dengue Vaccine Maria Rosario Z. Capeding, MD Research Institute for Tropical Medicine Philippines From
More informationMODULE 5. Dengue. Edwin J. Asturias Associate Professor of Pediatrics Senior Investigator Director for Latin America
MODULE 5 Dengue Edwin J. Asturias Associate Professor of Pediatrics Senior Investigator Director for Latin America Symptoms of Dengue Fever Dengue: Skin rashes DHF manifestations Hemorrhages Thrombocytopenia
More informationFlavivirus Vaccines Japanese Encephalitis and Dengue
Flavivirus Vaccines Japanese Encephalitis and Dengue 14 th Advanced Vaccinology Course Veyrier du Lac, France May 16, 2012 Harold S. Margolis, MD Dengue Branch Centers for Disease Control and Prevention
More informationDengue Experience and Implications for Vaccine Development
Dengue Experience and Implications for Vaccine Development In-Kyu Yoon, M.D. International Vaccine Institute Director, Global Dengue & Aedes-Transmitted Diseases Consortium 28 Jun 2018 Mission: To promote
More informationUpdated Questions and Answers related to the dengue vaccine Dengvaxia and its use
WHO Secretariat Updated Questions and Answers related to the dengue vaccine Dengvaxia and its use Published 22 December 2017 This document takes into account new and unpublished data that were communicated
More informationSummary of Key Points WHO Position Paper on Dengue Vaccine, September 2018
Summary of Key Points WHO Position Paper on Dengue Vaccine, September 2018 For more information on the WHO Dengue position paper, please visit the WHO website: www.who.int/immunization/documents/positionpapers
More informationDengue Vaccines: Status and Future
Dengue Vaccines: Status and Future In-Kyu Yoon, M.D. International Vaccine Institute Director, Global Dengue & Aedes-Transmitted Diseases Consortium 22 Jun 2018 Outline Tetravalent vaccination strategy
More informationA. Study Purpose and Rationale
IRB Proposal/CRC Rotation Sabrina J Gard, MD MPH Internal Medicine, PGY 1 5 May 2014 A. Study Purpose and Rationale Dengue is the most prevalent arthropod-transmitted virus, with conservative estimates
More informationDevelopment of dengue vaccines
Development of dengue vaccines Chee Siean Lim, Chit Laa Poh Centre for Virus and Vaccine Research, Sunway University, Selangor, Malaysia REVIEW Please cite this paper as: Lim CS, Poh CL. Development of
More informationHuman antibody response to dengue virus: implications for dengue vaccine design
Moi et al. Tropical Medicine and Health (2016) 44:1 DOI 10.1186/s41182-016-0004-y Tropical Medicine and Health REVIEW Human antibody response to dengue virus: implications for dengue design Meng Ling Moi
More informationPEDIATRIC INFECTIOUS DISEASE SOCIETY OF THE PHILIPPINES, INC.
RESPONSE FROM THE PEDIATRIC INFECTIOUS DISEASE SOCIETY OF THE PHILIPPPINES REGARDING CURRENT ISSUES ON THE USE OF THE DENGUE VACCINE 12 December 2017 In December 2015, the Philippines licensed the first
More informationDengue Vaccine Butantan Institute. DCVMN, Bangkok, 2015
Dengue Vaccine Butantan Institute DCVMN, Bangkok, 2015 GENOME Dengue Viruses Dengue is a mosquito-borne RNA virus with 4 distinct serotypes: 1,2,3,and 4 3 structural proteins: C, prm, and E E protein is
More informationDengue Update. Actualització sobre dengue
Leading research at: Dengue Update Click to edit Master subtitle style Actualització sobre dengue Ned Hayes, MD Dengue Leading research at: Caused by infection with one of 4 viruses DEN-1, DEN-2, DEN-3,
More informationLecture 9: Stochastic models for arboviruses. Ira Longini
Lecture 9: Stochastic models for arboviruses Ira Longini The Ross-MacDonald Model for Vector Bourne Infectious Diseases Sir Ronald Ross (1857-1932) Liverpool School of Tropical Medicine The 2 nd Nobel
More informationDengue vaccines: what we know, what has been done, but what does the future hold?
Rev Saúde Pública 2015;49:60 Comentário DOI:10.1590/S0034-8910.2015049006146 Emiliana Pereira Abrão Danillo Lucas Alves Espósito Flávio Lauretti Benedito Antonio Lopes da Fonseca Dengue vaccines: what
More informationOverview of a neglected infectious disease: dengue
Overview of a neglected infectious disease: dengue Outline Current epidemiological trends Mechanisms underlying dengue transmission Dengue control Overview of recent modeling efforts Drivers of serotype
More informationRecent advances in human flavivirus vaccines
Recent advances in human flavivirus vaccines Iris Scherwitzl 1, Juthathip Mongkolsapaya 1,2, Gavin Screaton 1 Addresses 1 Department of Medicine, Imperial College London, W12 0NN London, UK 2 Faculty of
More informationDependency of Vaccine Efficacy on Pre-Exposure and Age: A Closer Look at a Tetravalent Dengue Vaccine
Dependency of Vaccine Efficacy on Pre-Exposure and Age: A Closer Look at a Tetravalent Dengue Vaccine Yang Yang, PhD 1, Ya Meng, PhD 1, M. Elizabeth Halloran, DSc, MD 2,3, Ira M. Longini, Jr., PhD 1 August
More informationInternational Journal of Allied Medical Sciences
International Journal of Allied Medical Sciences and Clinical Research (IJAMSCR) IJAMSCR Volume 4 Issue 1 Jan Mar - 2016 www.ijamscr.com ISSN:2347-6567 Review article Medical research Thrombocyte: the
More informationPre-clinical Development of a Dengue Vaccine. Jeremy Brett Sanofi Pasteur, Singapore
Pre-clinical Development of a Dengue Vaccine Jeremy Brett Sanofi Pasteur, Singapore Dengue Vaccine B Guy 1 Talk flow Introduction: What are the challenges of dengue vaccine development? The Virus The host
More informationMaking Dengue a Vaccine Preventable Disease
Making Dengue a Vaccine Preventable Disease Harold S. Margolis, MD, FAAP Joint International Tropical Medicine Meeting (JITMM) Bangkok, Thailand October 13, 2008 Dengue Vaccines Where are We Today? No
More informationDengue vaccine: WHO position paper July 2016
Dengue vaccine: WHO position paper July 2016 References with abstracts cited in the position paper in the order of appearance. World Health Organization. Global Strategy for dengue prevention and control,
More informationCurrent Dengue Vaccine Status
Curr Trop Med Rep (2014) 1:6 12 DOI 10.1007/s40475-013-0006-3 VIRAL TROPICAL MEDICINE (CM BEAUMIER) Current Dengue Vaccine Status Leyi Lin & Stephen J. Thomas Published online: 21 December 2013 # Springer
More informationDeveloping a dengue vaccine: progress and future challenges
Ann. N.Y. Acad. Sci. ISSN 0077-8923 ANNALS OF THE NEW YORK ACADEMY OF SCIENCES Issue: Antimicrobial Therapeutics Reviews Developing a dengue vaccine: progress and future challenges Stephen J. Thomas Walter
More informationVaccines and immunization strategies for dengue prevention
OPEN (2016) 5, e77; doi:10.1038/emi.2016.74 www.nature.com/emi REVIEW Vaccines and immunization strategies for dengue prevention Yang Liu 1,2, Jianying Liu 1 and Gong Cheng 1 Dengue is currently the most
More informationA Recombinant Tetravalent Dengue Vaccine Candidate Using DENV-2 Backbone
A Recombinant Tetravalent Dengue Vaccine Candidate Using DENV-2 Backbone First Regional Dengue Symposium, Rio de Janeiro, Brazil Nov 3-4 2015 Pedro Garbes, MD. Regional Medical Director, Latin America.
More informationDengue Vaccines: current status of development
Dengue Vaccines: current status of development ISID-NTD 2011 International Meeting, Boston Satellite Symposium on Dengue Control, 10 July 2011 Pem Namgyal WHO/IVB/IVR 1 Presentation Outline! Summary of
More informationDengue Vaccine (CYD-TDV Dengvaxia )
Dengue Vaccine (CYD-TDV Dengvaxia ) Annelies Wilder-Smith Consultant, Vaccines for Arboviral Diseases, WHO-IVB Lee Kong Chian School of Medicine, Singapore Director, Partnership for Dengue Control, Fondation
More informationDOI: /ICJ poliovirus. [14] (Hand-Foot-Mouth Disease, HFMD) (Herpangina) 71 [26] [17,18,27] 71 picornaviridae
174 DOI: 10.6526/ICJ.2016.404 71 71 [14] (Hand-Foot-Mouth Disease, HFMD) (Herpangina) 71 71 picornaviridae poliovirus / 1990 71 [26] [17,18,27] 71 175 [31] ICR NOD/SCID AG129 hpsgl-1 hscarb2 (MP4) (MP4)
More informationAuchara Tangsathapornpong 1, Churairat Puriburt 2 and Pornumpa Bunjoungmanee 1
EPIDEMIOLOGY OF DENGUE AT THAMMASAT UNIVERSITY HOSPITAL DURING 2006-2015 Auchara Tangsathapornpong 1, Churairat Puriburt 2 and Pornumpa Bunjoungmanee 1 1 Department of Pediatrics, Faculty of Medicine,
More informationCYD-TDV Dengvaxia clinical update
Chris Nelson Sanofi Pasteur CYD-TDV Dengvaxia clinical update "Arboviruses: A Global Public Health Threat" 20-22 June 2018 Les Pensières Center for Global Health, Veyrier-du-Lac (France) JUNE 2018 1 The
More informationProspects for dengue vaccines for travelers
Special article CLINICAL EXPERIMENTAL VACCINE RESEARCH Prospects for dengue vaccines for travelers Clin Exp Vaccine Res 2016;5:89-100 pissn 2287-3651 eissn 2287-366X Sl-Ki Lim, Yong Seok Lee, Suk Namkung,
More informationInt.J.Curr.Microbiol.App.Sci (2018) 7(6):
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 7 Number 06 (2018) Journal homepage: http://www.ijcmas.com Original Research Article https://doi.org/10.20546/ijcmas.2018.706.128
More informationThe scope of the Zika pandemic and implications for vaccine development
The scope of the Zika pandemic and implications for vaccine development Jon Heinrichs, Ph.D. Associate Vice President & Segment Head Early and Pre-Development Projects Zika Vaccine Project Leader Emergence
More informationDengue fever. Dr Owen Tsang Princess Margaret Hospital 31 August 2018 ID forum
Dengue fever Dr Owen Tsang Princess Margaret Hospital 31 August 2018 ID forum World figures 登革热风险地区 没有登革热风险地区 1970 2004 Epidemiology WHO reports 30x increase in cases since 1960 No. of countries reporting
More informationReview on murine models available for dengue vaccine development
Indian Journal of Natural Products and Resources Vol. 7(3), September 2016, pp. 201-206 Review on murine models available for dengue vaccine development Akash Parthi Bendran 1, Vikneswaran Murugaiyah 2
More informationSeroprevalence and Recent Trends of Dengue in a Rural Area in South India
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 6 Number 1 (2017) pp. 36-41 Journal homepage: http://www.ijcmas.com Original Research Article http://dx.doi.org/10.20546/ijcmas.2017.601.005
More informationEvaluating the Impact of a Tetravalent Vaccine in Populations with High-Incidence of Dengue: A Mathematical Model
Nonlinear Analysis and Differential Equations, Vol. 4, 216, no. 3, 133-142 HIKARI Ltd, www.m-hikari.com http://dx.doi.org/1.12988/nade.216.51148 Evaluating the Impact of a Tetravalent Vaccine in Populations
More informationWhat is the role of animal models in studying protective titres and the need for establishing surrogates/correlates of protection?
What is the role of animal models in studying protective titres and the need for establishing surrogates/correlates of protection? Alan D.T. Barrett Department of Pathology and Sealy Center for Vaccine
More informationSAGE deliberations on CYD-TDV ( Dengvaxia )
SAGE deliberations on CYD-TDV ( Dengvaxia ) Annelies Wilder-Smith Consultant, Vaccines for Arboviral Diseases, WHO-IVB Scientific Coordinator ZIkaPLAN Director, Partnership for Dengue Control, Fondation
More informationWe are IntechOpen, the first native scientific publisher of Open Access books. International authors and editors. Our authors are among the TOP 1%
We are IntechOpen, the first native scientific publisher of Open Access books 3,350 108,000 1.7 M Open access books available International authors and editors Downloads Our authors are among the 151 Countries
More informationSymptomatic Dengue in Children in 10 Asian and Latin American Countries
The new england journal of medicine Original Article Symptomatic Dengue in Children in 10 Asian and Latin American Countries Maïna L Azou, M.Sc., Annick Moureau, M.Sc., Elsa Sarti, Ph.D., Joshua Nealon,
More informationFlaviviruses New Challenges, New Vaccines
Flaviviruses New Challenges, New Vaccines Christian W. Mandl Institute of Virology Medical University of Vienna, AUSTRIA Family Flaviviridae Genus Hepacivirus Genus Pestivirus Genus Flavivirus (>70 members)
More informationVaccine prevention for existing and emerging viral threats
Vaccine prevention for existing and emerging viral threats Viruses in May Blue Mountains 18 May 2018 www.ncirs.edu.au https://www.apprise.org.au/ Prof Kristine Macartney Director, NCIRS www.ncirs.usyd.edu.au
More informationAntibody Recognition of the Dengue Virus Proteome and Implications for Development of Vaccines
CLINICAL AND VACCINE IMMUNOLOGY, Apr. 2011, p. 523 532 Vol. 18, No. 4 1556-6811/11/$12.00 doi:10.1128/cvi.00016-11 Copyright 2011, American Society for Microbiology. All Rights Reserved. Antibody Recognition
More informationReceived 26 September 2009/Returned for modification 29 October 2009/Accepted 18 December 2009
CLINICAL AND VACCINE IMMUNOLOGY, Mar. 2010, p. 402 407 Vol. 17, No. 3 1556-6811/10/$12.00 doi:10.1128/cvi.00396-09 Copyright 2010, American Society for Microbiology. All Rights Reserved. Discrepancy in
More informationDengue vaccine โดย ศ. พญ. ก ลก ญญา โชคไพบ ลย ก จ ภาคว ชาก มารเวชศาสตร คณะแพทยศาสตร ศ ร ราชพยาบาล
Dengue vaccine โดย ศ. พญ. ก ลก ญญา โชคไพบ ลย ก จ ภาคว ชาก มารเวชศาสตร คณะแพทยศาสตร ศ ร ราชพยาบาล SANOFI PASTEUR S DENGUE VACCINE*: THE MOST CLINICALLY ADVANCED DENGUE VACCINE CANDIDATE There are 4 genetic
More informationAdvaita Ganguly, Ravindra B Malabadi, Raimer Loebenberg, Mavanur R Suresh and Hoon H Sunwoo*
Research in Pharmacy 3(2): 18-25, 2013 ISSN : 2231-539X www.researchinpharmacy.com Mini Review A Mini-review of Dengue Vaccine Development Advaita Ganguly, Ravindra B Malabadi, Raimer Loebenberg, Mavanur
More informationLong-term Immunogenicity Following Vaccination with a New, Live-attenuated Vaccine Against Japanese Encephalitis (JE-CV)
Long-term Immunogenicity Following Vaccination with a New, Live-attenuated Vaccine Against Japanese Encephalitis (JE-CV) Sutee Yoksan, M.D., Ph.D. Center for Vaccine Development, Mahidol University Joint
More informationUK Journal of Pharmaceutical and Biosciences Available at ISSN:
UK Journal of Pharmaceutical and Biosciences Vol. 4(2), 58-62, 2016 RESEARCH ARTICLE UK Journal of Pharmaceutical and Biosciences Available at www.ukjpb.com ISSN: 2347-9442 AB Initio Structural Analysis
More informationTowards Dengue Vaccine
Towards Dengue Vaccine by Dr Shee-Mei Lok DUKE- NUS Graduate Medical School, Singapore Dengue fever is endemic in tropical and sub-tropical countries affecting approximately 100 million people each year.
More informationDengue Virus-Danger from Deadly Little Dragon
Molecular Medicine Dengue Virus-Danger from Deadly Little Dragon Dr.G.MATHAN Assistant Professor Department of Biomedical Science Bharathidasan University Tiruchirappalli, Tamil Nadu Vector (A carrier)
More informationCorrelates of Protection in Dengue. Stephen J. Thomas, MD Division of Infectious Diseases State University of New York Upstate Medical University
Correlates of Protection in Dengue Stephen J. Thomas, MD Division of Infectious Diseases State University of New York Upstate Medical University May 2017 Discussion of correlates requires clarity and proper
More informationPart B. Nonclinical evaluation of dengue tetravalent vaccines (live, attenuated) 81
Annex 2 Guidelines on the quality, safety and efficacy of dengue tetravalent vaccines (live, attenuated) Replacement of Annex 1 of WHO Technical Report Series, No. 932 Abbreviations 55 Introduction 55
More informationANTIBODIES DETERMINE VIRULENCE IN DENGUE. Scott B HALSTEAD, M.D. DIRECTOR, Research Pediatric Dengue Vaccine Initiative IVI, Seoul, Korea
ANTIBODIES DETERMINE VIRULENCE IN DENGUE Scott B HALSTEAD, M.D. DIRECTOR, Research Pediatric Dengue Vaccine Initiative IVI, Seoul, Korea Global Spread of Dengue 50-100 million infections/year Countries
More informationArboviruses: A Global Public Health Threat
Arboviruses: A Global Public Health Threat Les Pensières Center for Global Health Veyrier-du-Lac - France 20-22 June 2018 Steering Committee: Duane Gubler Mauricio Lacerda Nogueira Jacques Louis Christopher
More informationImpact of Dengue Vaccination on Serological Diagnosis: Insights From Phase III Dengue Vaccine Efficacy Trials
Clinical Infectious Diseases MAJOR ARTICLE Impact of Dengue Vaccination on Serological Diagnosis: Insights From Phase III Dengue Vaccine Efficacy Trials Eric Plennevaux, 1 Annick Moureau, 2 José L. Arredondo-García,
More informationComputational prediction of immunodominant antigenic regions & potential protective epitopes for dengue vaccination
Indian J Med Res 144, October 2016, pp 587-591 DOI: 10.4103/0971-5916.200894 Quick Response Code: Computational prediction of immunodominant antigenic regions & potential protective epitopes for dengue
More informationsp second generation tetravalent dengue vaccine
sp second generation tetravalent dengue vaccine CYD23 Study Efficacy and Safety of Dengue Vaccine in Healthy Children Aged 4 to 1 Years in Thailand Alain Bouckenooghe, MD, MPH, DTM&H Clinical R&D, Head
More informationDevelopment of a Recombinant Subunit Dengue Vaccine. Flavivirus Vaccination Fondation Mérieux December 8, 2010 Beth-Ann Coller
Development of a Recombinant Subunit Dengue Vaccine Flavivirus Vaccination Fondation Mérieux December 8, 2010 Beth-Ann Coller Recombinant Subunit Dengue Vaccine Recombinant Envelope Protein Vaccine Hawaii
More informationThe Effectiveness of Dengue Vaccine and Vector Control: Model Study
KMUTNB Int J Appl Sci Technol, Vol. 11, No. 3, pp. 225 232, 218 Research Article The Effectiveness of Dengue Vaccine and Vector Control: Model Study Sittisede Polwiang* Department of Mathematics, Faculty
More informationThe DENGUE Vaccine. Salvacion Rodriguez Gatchalian, MD, FPPS, FPISP, FPSMID Associate Professor, UP College of Medicine
The DENGUE Vaccine Salvacion Rodriguez Gatchalian, MD, FPPS, FPISP, FPSMID Associate Professor, UP College of Medicine GLOBAL DENGUE FACTS 2.5 billion people, or 40% of the world s population, live in
More informationGuidelines on the quality, safety and efficacy of dengue tetravalent vaccines (live, attenuated)
ENGLISH ONLY FINAL Guidelines on the quality, safety and efficacy of dengue tetravalent vaccines (live, attenuated) Proposed replacement of Annex 1 of WHO Technical Report Series, No. 932 World Health
More informationNS1 Protein Expression in the JaOArS982 Strain of Japanese Encephalitis Virus Does Not Enhance Virulence in Mice
Tropical Medicine and Health Vol. 43 No.4, 2015, 233 237 doi: 10.2149/tmh.2015-27 Copyright 2015 by The Japanese Society of Tropical Medicine 233 Short Communications NS1 Protein Expression in the JaOArS982
More informationDengue: a trilogy of people, mosquitoes and the virus. Current epidemiology and pathogenesis in (non-)endemic settings Thai, K.T.D.
UvA-DARE (Digital Academic Repository) Dengue: a trilogy of people, mosquitoes and the virus. Current epidemiology and pathogenesis in (non-)endemic settings Thai, K.T.D. Link to publication Citation for
More informationFuture Directions of Diagnosis and Treatment of Dengue Virus
International Journal of Bioinformatics and Biomedical Engineering Vol. 4, No. 3, 2018, pp. 50-55 http://www.aiscience.org/journal/ijbbe ISSN: 2381-7399 (Print); ISSN: 2381-7402 (Online) Future Directions
More informationDengue pathogenesis and vaccine design
Dengue pathogenesis and vaccine design Dengue 390 million cases worldwide each year Fever to severe hemorrhaging and shock No effective vaccine Tropical disease on the move Dengue disease worldwide WHO
More informationJoseph E. Blaney, Jr.,* Jennifer M. Matro, Brian R. Murphy, and Stephen S. Whitehead
JOURNAL OF VIROLOGY, May 2005, p. 5516 5528 Vol. 79, No. 9 0022-538X/05/$08.00 0 doi:10.1128/jvi.79.9.5516 5528.2005 Recombinant, Live-Attenuated Tetravalent Dengue Virus Vaccine Formulations Induce a
More informationCross-reactive dengue virus-derived monoclonal antibodies to Zika virus envelope protein: Panacea or Pandora s box?
Gunawardana and Shaw BMC Infectious Diseases (2018) 18:641 https://doi.org/10.1186/s12879-018-3572-0 DEBATE Open Access Cross-reactive dengue virus-derived monoclonal antibodies to Zika virus envelope
More informationNew prospects for vaccination: from polio to dengue and flu
New prospects for vaccination: from polio to dengue and flu From ancient Chinese variolation to Jenner and cowpox Paul Young Australian Infectious Diseases Research Centre School of Chemistry and Molecular
More informationImmunopathogenesis of Dengue Hemorrhagic Fever
Immunopathogenesis of Dengue Hemorrhagic Fever Carlos A. Sariol, MD, MS. Associated Investigator School of Medicine, MSC-UPR September 17th, 2009 Foro Educativo para Maestros de Ciencias en la UPRH September
More informationWHO Working Group on Technical Specifications for Manufacture and Evaluation of Dengue Vaccines
Distribution: General English only Meeting Report WHO Working Group on Technical Specifications for Manufacture and Evaluation of Dengue Vaccines Geneva, Switzerland 11-12 May 2009 1 1 Disclaimer: This
More informationUNIVERSITI TEKNOLOGI MARA COPY NUMBER VARIATION OF FCGR3B GENE AMONG SEVERE DENGUE PATIENT IN MALAYSIA
UNIVERSITI TEKNOLOGI MARA COPY NUMBER VARIATION OF FCGR3B GENE AMONG SEVERE DENGUE PATIENT IN MALAYSIA UMI SHAKINA HARIDAN Thesis submitted in fulfilment of the requirements for the degree of Master of
More informationTel:
A/Prof Joe Torresi Department of Infectious Diseases Austin Hospital Austin Centre for Infection Research Department of Medicine (Austin Health) The University of Melbourne Tel: 61 3 9496 6676 josepht@unimelb.edu.au
More informationMathematical Models for the Control of Infectious Diseases With Vaccines
Mathematical Models for the Control of Infectious Diseases With Vaccines Ira Longini Department of Biostatistics and Center for Statistical and Quantitative Infectious Diseases (CSQUID), University of
More informationDengue: defining protective versus pathologic immunity
Review series Dengue: defining protective versus pathologic immunity Alan L. Rothman Center for Infectious Disease and Vaccine Research, University of Massachusetts Medical School, Worcester, Massachusetts,
More informationBioinformation by Biomedical Informatics Publishing Group
Predicted RNA secondary structures for the conserved regions in dengue virus Pallavi Somvanshi*, Prahlad Kishore Seth Bioinformatics Centre, Biotech Park, Sector G, Jankipuram, Lucknow 226021, Uttar Pradesh,
More informationREVIEW ARTICLE. Understanding Dengue and Implications for Prevention
ISSN 2455 3549 Volume 2/ Issue 6 / June 2016: 1-6 REVIEW ARTICLE Understanding Dengue and Implications for Prevention N. Akila *, R. Sathi Kumaran Department of Zoology, Pachaiyappa s College, Chennai
More informationDengue: a growing threat requiring vaccine development for disease prevention
Pathogens and Global Health ISSN: 2047-7724 (Print) 2047-7732 (Online) Journal homepage: https://www.tandfonline.com/loi/ypgh20 Dengue: a growing threat requiring vaccine development for disease prevention
More informationChapter - 1 INTRODUCTION
Chapter - 1 INTRODUCTION Page 1.1 Dengue Virus Structure and types of infection caused by the virus 2 1.2 WHO Classification of Dengue 4 1.3 Laboratory Diagnosis of Dengue 5 1.4 Aims and Objectives 9 1.5
More informationEBioMedicine 13 (2016) Contents lists available at ScienceDirect. EBioMedicine. journal homepage:
EBioMedicine 13 (201) 24 293 Contents lists available at ScienceDirect EBioMedicine journal homepage: www.ebiomedicine.com Research Paper Protective Role of Cross-Reactive CD T Cells Against Dengue Virus
More informationProposal for a Workshop
Proposal for a Workshop Pre-vaccination screening for the use of dengue vaccines with differential performance dependent on serostatus: rapid diagnostic tests and implementation strategies Background:
More informationPerspective Piece Licensed Dengue Vaccine: Public Health Conundrum and Scientific Challenge
Am. J. Trop. Med. Hyg., 95(4), 2016, pp. 741 745 doi:10.4269/ajtmh.16-0222 Copyright 2016 by The American Society of Tropical Medicine and Hygiene Perspective Piece Licensed Dengue Vaccine: Public Health
More informationDownloaded by on April 28, 2018 https://pubs.acs.org Publication Date: April 24, 1984 doi: /bk
1 Virus-Receptor Interactions BERNARD N. FIELDS Department of Microbiology and Molecular Genetics, Harvard Medical School, and Department of Medicine (Infectious Disease), Brigham and Women's Hospital,
More informationReceived 13 February 2008/Accepted 14 April 2008
JOURNAL OF VIROLOGY, July 2008, p. 6631 6643 Vol. 82, No. 13 0022-538X/08/$08.00 0 doi:10.1128/jvi.00316-08 Copyright 2008, American Society for Microbiology. All Rights Reserved. Antibodies to Envelope
More informationINTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH AND BIO-SCIENCE
INTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH AND BIO-SCIENCE IMPACT OF DENGUE VIRUS ON INNATE AND ADAPTIVE IMMUNE SYSTEM AMIT GUPTA, SUSHAMA R CHAPHALKAR Department of Immunology, Vidya Pratishthan
More informationStudying Repeated Immunization in an Animal Model. Kanta Subbarao Laboratory of Infectious Diseases, NIAID
Studying Repeated Immunization in an Animal Model Kanta Subbarao Laboratory of Infectious Diseases, NIAID Animal models in Influenza Research Commonly used Mice Ferrets Guinea pigs Non human primates Less
More informationAnimal models for dengue vaccine development and testing
Review article CLINICAL EXPERIMENTAL VACCINE RESEARCH Animal models for dengue vaccine development and testing Clin Exp Vaccine Res 2017;6:104-110 pissn 2287-3651 eissn 2287-366X Woonsung Na*, Minjoo Yeom*,
More informationDengue Update. Disclosures 7/29/2018. Adam C. Hunt, D.O., M.H.S. Covenant Emergency Care Center, Saginaw, MI
Dengue Update Adam C. Hunt, D.O., M.H.S. Covenant Emergency Care Center, Saginaw, MI Disclosures None This lecture is 99.6% free of any Russian collusion 1 Goals/Objectives 1. Epidemiology of Dengue 2.
More informationEPIDEMIOLOGICAL STUDIES
EPIDEMIOLOGICAL STUDIES EPIDEMIOLOGIC STUDIES EPIDEMIOLOGIC STUDIES 8 Clinical Trial sites in Brasil (NICHD) Transfusion recipient study (NHLBI) Prospective study in Brasil (Yale) Natural history population
More informationNASRONUDIN 4/17/2013. DENVs of each type are grouped into several genotypes.
NASRONUDIN Institute of Tropical Disease, Airlangga University-Tropical and Infectious Diseases Division, Department of Internal Medicine Medical Faculty-Dr. Soetomo Hospital Disampaikan pada 14 th Jakarta
More informationProtection of Rhesus Monkeys against Dengue Virus Challenge after Tetravalent Live Attenuated Dengue Virus Vaccination
MAJOR ARTICLE Protection of Rhesus Monkeys against Dengue Virus Challenge after Tetravalent Live Attenuated Dengue Virus Vaccination Wellington Sun, 1 Ananda Nisalak, 3 Montip Gettayacamin, 4 Kenneth H.
More informationSubstitution or deletion mutations between nt 54 and 70 in the 59 non-coding region of dengue type 2 virus produce variable effects on virus viability
Journal of General Virology (2007), 88, 1748 1752 DOI 10.1099/vir.0.82455-0 Short Communication Correspondence Vijittra Leardkamolkarn scvlk@mahidol.ac.th Substitution or deletion mutations between nt
More informationUpdate on the NIH tetravalent dengue vaccine. Beulah Sabundayo, PharmD, MPH Johns Hopkins Bloomberg School of Public Health
Update on the NIH tetravalent dengue vaccine Beulah Sabundayo, PharmD, MPH Johns Hopkins Bloomberg School of Public Health 1 Tetravalent studies in DENV naïve adults Potency (log Vaccine Components: 10
More informationUsa Thisyakorn and Chule Thisyakorn
CHILDHOOD DENGUE DISEASES: A TWENTY YEARS PROSPECTIVE STUDY Usa Thisyakorn and Chule Thisyakorn Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand Abstract. Dengue
More information